Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Showing 1 to 12 of 449 entries
Sorted by: Best Match Show Resources per page
Brentuximab Vedotin Infusion Reaction Management: A Case Study.

Journal of the advanced practitioner in oncology

Comer H, Cardwell K.
PMID: 30310723
J Adv Pract Oncol. 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 01.

We report a case of a grade 3 (Common Terminology Criteria for Adverse Events [CTCAE]) infusion reaction to brentuximab vedotin (Adcetris), in a patient with refractory Hodgkin lymphoma, at a large National Cancer Institute-designated cancer center in the Midwest...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.

Contemporary clinical trials communications

Pfister C, Harter V, Allory Y, Radvanyi F, Culine S.
PMID: 32083220
Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar.

The main objective of the French GETUG/AFU V05 VESPER randomized phase III study was to assess the efficacy of dd-MVAC and GC in term of progression-free survival in patients for whom chemotherapy has been decided, before or after surgery....

Primary Oro-Facial Manifestations of Langerhans Cell Histiocytosis in Pediatric Age: A Bi-Institutional Retrospective Study on 45 Cases.

Children (Basel, Switzerland)

Capodiferro S, Tempesta A, Limongelli L, Ingravallo G, Maiorano E, Sfasciotti GL, Bossù M, Polimeni A, Favia G.
PMID: 32825016
Children (Basel). 2020 Aug 19;7(9). doi: 10.3390/children7090104.

AIMS: Langerhans Cell Histiocytosis is a rare hematologic disorder usually affecting children and most commonly involving the head and neck region. Primary oro-facial manifestations are rare, and their diagnosis is often challenging as they are numerous and often resemble...

Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease.

Seminars in radiation oncology

Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M.
PMID: 10717177
Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185.

Recommendations for the treatment of "poor prognosis" stages I and II Hodgkin's disease (HD) depend on the extent of staging. For centers that favor exploratory laparotomy and splenectomy, the standard treatment after negative surgical staging remains subtotal lymphoid irradiation....

Gliomas in children.

Current treatment options in neurology

Minturn JE, Fisher MJ.
PMID: 23440592
Curr Treat Options Neurol. 2013 Jun;15(3):316-27. doi: 10.1007/s11940-013-0225-x.

OPINION STATEMENT: Gliomas are the most common brain tumor in children and represent nearly 50 % of all pediatric central nervous system (CNS) tumors. They are a heterogeneous group of diseases, ranging from highly malignant and frequently fatal to...

Pregnancy in a patient with cancer and heart failure: challenges and complexities.

Journal of the advanced practitioner in oncology

Fadol AP, Lech T, Bickford C, Yusuf SW.
PMID: 25031933
J Adv Pract Oncol. 2012 Mar;3(2):85-93. doi: 10.6004/jadpro.2012.3.2.3.

A 24-year-old African American female (L.R.) with a history of smoking and gestational diabetes was diagnosed with Hodgkin lymphoma. She received multiple chemotherapies, including six cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), followed by radiation therapy to left...

The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy.

Journal of blood medicine

Bayoumi Y, Al-Homaidi A, Zaidi S, Tailor I, Motiabi I, Alshehri N, Al-Ghazali A, Almudaibigh S.
PMID: 25848329
J Blood Med. 2015 Mar 20;6:87-92. doi: 10.2147/JBM.S69267. eCollection 2015.

BACKGROUND/PURPOSE: The aim of this study was to evaluate the role of consolidation radiotherapy (RT) in advanced-stage Hodgkin's disease (HD) with initial bulky sites after radiological complete remission (CR) or partial response (PR) with positron emission tomography-negative (metabolic CR)...

A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.

Frontiers in immunology

Liu Z, Tang Q, Qi T, Othmane B, Yang Z, Chen J, Hu J, Zu X.
PMID: 34484235
Front Immunol. 2021 Aug 13;12:725223. doi: 10.3389/fimmu.2021.725223. eCollection 2021.

BACKGROUND: Bladder cancer (BLCA) is one of the most common urinary malignancies with poor prognosis. There is an unmet need to develop novel robust tools to predict prognosis and treatment efficacy for BLCA.METHODS: The hypoxia-related genes were collected from...

In vitro Cytotoxic Activities and Molecular Mechanisms of Angelica shikokiana Extract and its Isolated Compounds.

Pharmacognosy magazine

Mira A, Shimizu K.
PMID: 27013795
Pharmacogn Mag. 2015 Oct;11:S564-9. doi: 10.4103/0973-1296.172962.

BACKGROUND: Angelica shikokiana is a Japanese medicinal herb that is included among food and drug preparations protecting against cancer; however, there is no previous report about the cytotoxicity of A. shikokiana or its bioactive compounds.OBJECTIVE: This study was designed...

Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature.

Journal of the International AIDS Society

Sculier D, Doco-Lecompte T, Rougemont M, Calmy A.
PMID: 25394154
J Int AIDS Soc. 2014 Nov 02;17(4):19650. doi: 10.7448/IAS.17.4.19650. eCollection 2014.

INTRODUCTION: In HIV patients, haemophagocytic syndrome (HPS) may occur in the presence of cancer, concomitant viral infection, HIV primo-infection or at the initiation of highly active antiretroviral therapy (HAART). Hodgkin lymphoma remains a rare cause of HPS. We describe...

Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.

International journal of radiation oncology, biology, physics

Baues C, Goergen H, Fuchs M, Rosenbrock J, Celik E, Eich H, Kobe C, Voltin CA, Engert A, Borchmann P, Marnitz S.
PMID: 34389407
Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):900-906. doi: 10.1016/j.ijrobp.2021.07.1697. Epub 2021 Aug 11.

PURPOSE: The HD16 trial of the German Hodgkin Study Group (NCT00736320) demonstrated that radiation therapy in early-stage Hodgkin lymphoma without risk factors cannot be safely omitted, and therefore combined modality therapy (CMT) remains the standard treatment. To demonstrate the...

MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines.

Prostate cancer and prostatic diseases

Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST, Parkin JD.
PMID: 12497102
Prostate Cancer Prostatic Dis. 2000 Aug;3(2):66-75. doi: 10.1038/sj.pcan.4500394.

Multidrug resistant prostate cancer cell lines DU 0.03 and PC 0.03 were established from the parental prostate cancer cell lines DU145 and PC-3 respectively by stepwise selection in doxorubicin (DOX) from 0.001 to 0.03 &mgr;g/ml. As cells adapted to...

Showing 1 to 12 of 449 entries